

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/509,599
International Filing Date	March 21, 2003
First Named Inventor	DELANEY, Allen D.
Art Unit	
Examiner Name	
Attorney Docket Number	SMAR-043

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/B.F./	A1	US 2002026226		02-28-2002	Incyte Genomics, Inc.	
	A2	US 2002142953		10-03-2002	Hyseq, Inc.	
	A3	US 2002146692		10-10-2002	Hyseq, Inc.	
	A4	US 2002197679		12-26-2002	Hyseq, Inc.	
	A5	US 2003104529		06-05-2003	Hyseq, Inc.	
	A6	US 2003138793		07-24-2003	IRM LLC	
	A7	US 5,707,829		01-13-1998	Genetics Institute, Inc.	
	A8	US 5,962,232		10-05-1999	Incyte Pharmaceuticals, Inc.	
	A9	US 5,962,312		10-05-1999	Sugen, Inc.	
	A10	US 5,972,676		10-26-1999	Sugen, Inc.	
	A11	US 6,013,500		01-11-2000	The Trustees of Columbia University in the City of New York	
	A12	US 6,124,272		09-26-2000	Isis Pharmaceuticals Inc.	
	A13	US 6,124,272		09-26-2000	Isis Pharmaceuticals Inc.	
	A14	US 6,207,401		03-27-2001	Sugen, Inc.	
	A15	US 6,465,620		10-15-2002	Hyseq, Inc.	
	A16	US 6,500,938B1		12-31-2002	Seilhamer, Jeffrey J., et al.	
	A17	US 6,569,662		05-27-2003	Hyseq, Inc.	
/B.F./	A18	US 6,586,390		07-01-2003	Hyseq, Inc.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
/B.F./	B1	WO	00/6728	A	02-10-2000	Incyte Pharmed Inc.		
	B2	WO	01/53312	A	07-26-2001	Hyseq, Inc.		
	B3	WO	01/81555	A	11-01-2001	Incyte Genomics Inc.		
	B4	WO	02/01357	A	12-19-2002	IRM LLC		
	B5	WO	97/02357		01-23-1997	Affymetrix, Inc.		
	B6	WO	01/36602		05-25-2001	Pharmacia and Upjohn S.P.A.		
	B7	WO	99/53036		10-21-1999	Sugen, Inc.		
/B.F./	B8	WO	00/56864		09-28-2000	University of Dundee		

Examiner
Signature

/Brandon Fetterolf/

Date
Considered

04/03/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number

10/509,599

International Filing Date

March 21, 2003

First Named Inventor

DELANEY, Allen D.

Art Unit

Examiner Name

Attorney Docket Number

SMAR-043

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
/B.F./	B9	WO	00/73469A3 ✓	12-07-2000	Sugen, Inc.		
	B10	WO	01/42467 ✓	06-14-2001	Millenium Predictive Medicine, Inc.		
	B11	WO	01/44497 ✓	06-21-2001	University of Dundee		
	B12	WO	01/57058 ✓	08-09-2001	Metagen Gesellschaft Fur Genomforschung MBH		
	B13	WO	01/77389 ✓	10-18-2001	Incyte Genomics, Inc.		
	B14	WO	02/29103 ✓	04-11-2002	Gene Logic, Inc.		
	B15	WO	92/19258 ✓	11-12-1992	Childrens Hospital of Los Angeles		
	B16	WO	97/22702 ✓	06-27-1997	Sugen, Inc.		
	B17	WO	98/41638 ✓	09-24-1998	Medical Research Council		
	B18	WO	99/37788 ✓	07-29-1999	Sugen, Inc.		
	B19	WO	99/63073 ✓	10-09-1999	The Trustees of Columbia University in the City of New York		
/B.F./	B20	WO	99/64576 /	12-16-1999	Bayer Corporation		

Examiner
Signature

/Brandon Fetterolf/

Date
Considered

04/03/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	
International Filing Date	March 21, 2003
First Named Inventor	DELANEY, Allen D.
Art Unit	
Examiner Name	
Attorney Docket Number	SMAR-043

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./	C1	ABO, A., et al. "PAK4, a novel effector Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia". EMBO Journal, (1998), 17(22):6527-40	
	C2	ALESSI, D.R., James, S.R. and Downs, C.P., et al. "Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balph", Curr Biol (1997) 7(4):261-9	
	C3	CROSS, T.G., et al. "Serine/threonine protein kinases and apoptosis". Exp Cell Res, (2000), 256(1):34-41	
	C4	DREWES, G., et al. "MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption". Cell (1997), 89(2):297-308	
	C5	DUESTERHOEFT, A. and Lauber, J. and Mewes, H.W., et al. MIPS A.M. Klopferspitz 18a, D-82152 Martinsried Germany Genbank Submission	
	C6	HAYASHI, A., et al. "PKCnu, a new member of the protein kinase C family, composed fourth subfamily with PKCmu". Biochim Biophys Acta (1999) 1450(1):99-106	
	C7	JOHANNES, F.J., et al. "PKCu is a novel, atypical member of the protein kinase C family". J Biol Chem (1994), 269(8):6140-8	
	C8	KANDLI, M., et al. "Isolation and characterization of two evolutionarily conserved murine kinases (Nek6 and nek7) related to the fungal mitotic regulator, NIMA". Genomics (2000), 68(2):187-96	
	C9	KIMURA, M., et al. "Cell cycle-dependent expression and spindle pole localization of novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1". J Biol Chem (1997) 272(21):13766-7	
	C10	KIMURA, M., et al. "Assignment of STK6 to human chromosome 20q13.2-->113.3 and a pseudogene STK6P to 1q41--q42". Cytogenet Cell Genet (1997), 79(3-4):201-3	
	C11	KO, T.K., et al. "CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles". J Cell Sci, (2001), 114(Pt 14):2591-2603	
	C12	KOLOBOVA, E., et al. "Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites". Biochem J (2001), 358(Part 1): 69-77	
	C13	LAZZARO, M.A., et al. "A novel cdc2-related protein kinase expressed in the nervous system". J. Neurochem, (1997), 69(1):348-64	
/B.F./	C14	MADAULE, P., et al. "Role of citron kinase as a target of the small GTPase Rho in cytokinesis". Nature (1998) 394(6692):491-4	

Examiner
Signature

/Brandon Fetterolf/

Date
Considered

04/03/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	
International Filing Date	March 21, 2003
First Named Inventor	DELANEY, Allen D.
Art Unit	
Examiner Name	
Attorney Docket Number	SMAR-043

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./	C15	MEYERSON, M., et al. "A family of human cdc2-related protein kinases". EMBO Journal, (1992), 11(8):2909-2917	
	C16	NAGASE, T., Ishikawa, A. and Suyama, M., et al. "Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". DNA Res (1998) 5(6):355-364	
	C17	OKUDA, T., et al. "Cloning of genomic loci and chromosomal localization of the human PCTAIRE-1 and -3 protein kinase genes". Genomics (1994), 21(1):217-221	
	C18	PINES, J.N. and Kelly, E. CDC2-related protein kinase 7 [homosapiens] DB Source Refseq: accession NM_016507.1	
	C19	PULLEN, N., et al. "Phosphorylation and activation of p70s6k by PDK1". Science (1998), 279(5351):707-10	
	C20	QIU, Y., et al. "Signaling network of the Btk family kinases". Oncogene (2000), 19:5651-61	
	C21	SILICIANO, J.D., et al. "itk, a T-cell-specific tyrosine kinase gene inducible by interleukin 2". PNAS USA (1992), 89(23):11194-8	
/B.F./	C22	WAMBUTT, I., Heubner, D. and Mewes, H.W., et al. Direct submission to Genbank submitted March 10, 1999. MIPS Accession No. AL050147	

Examiner
Signature

/Brandon Fetterolf/

Date
Considered

04/03/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.